[Skip to Content]
[Skip to Content Landing]
Views 494
Citations 0
Observation
April 2018

Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme

Author Affiliations
  • 1Department of Dermatology, Assistance Publique–Hôpitaux de Paris, Henri Mondor Hospital, Créteil, France
  • 2EA 7379 EpiDermE (Epidemiologie en Dermatologie et Evaluation des Thérapeutiques), Université Paris–Est Créteil Val de Marne, Créteil, France
  • 3Referral Center for Toxic Bullous Diseases, Créteil, France
  • 4Department of Immunology, Assistance Publique–Hôpitaux de Paris, Bichat Hospital, Paris, France
  • 5Université Paris–Est Créteil Val de Marne, Créteil, France
JAMA Dermatol. 2018;154(4):487-489. doi:10.1001/jamadermatol.2017.5889

Erythema multiforme (EM) is a hypersensitivity skin condition involving T-cell and B-cell responses for which the main causes are infectious factors (eg, herpes simplex virus, Mycoplasma pneumoniae). Antiplakin autoantibodies are found in some patients. EM has a chronic course (ie, recurrent or subintrant) in 40% of cases. Mucous membrane involvement causes relevant morbidity and impairs quality of life.1

×